Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 17/20 | 0.67 |
| ▸ | VEGFA | P15692 | 6/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16555957 | 1.00 | EPAS1 (0.67) | EPAS1VEGFA | |
| SCHEMBL19870699 | 0.86 | EPAS1 (0.67) | EPAS1VEGFA | |
| SCHEMBL16556281 | 0.80 | EPAS1 (1.00) | EPAS1VEGFA | |
| SCHEMBL31497856 | 0.78 | EPAS1 (0.66) | EPAS1VEGFA | |
| SCHEMBL26812490 | 0.78 | EPAS1 (0.67) | EPAS1VEGFA | |
| SCHEMBL21005497 | 0.76 | VEGFA (0.86) | EPAS1VEGFA | |
| SCHEMBL16560890 | 0.76 | VEGFA (0.86) | EPAS1VEGFA | |
| SCHEMBL20650904 | 0.74 | EPAS1 (0.79) | EPAS1VEGFA | |
| SCHEMBL18053108 | 0.73 | EPAS1 (0.74) | EPAS1VEGFA | |
| SCHEMBL16555388 | 0.72 | EPAS1 (0.66) | EPAS1VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10786480-B2 | Combination therapy of a HIF-2-α inhibitor and an immunotherapeutic agent and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| EP-3043784-B9 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS INC (US) | 2019-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10786480-B2 | Combination therapy of a HIF-2-α inhibitor and an immunotherapeutic agent and uses thereof | HIF1AN, HIF1A, EGLN2 | EPAS1 16/4885VEGFA 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.